[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628221":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":47,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D arm","ACTIVE_COMPARATOR","Vitamin D 4000 IU daily for 2 weeks followed by 1000 IU for 24 weeks",[13],"Drug: Vitamin D",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","No vitamin D",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Vitamin D","Vitamin D 4000 IU daily for 2 weeks followed by 1000 IU daily for 24 weeks",[9],[26],{"name":27,"affiliation":5,"role":28},"Kay Cheong Teo, MBBS, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","852-22552368","kcteo@hku.hk",[35],{"facility":5,"status":36,"city":37,"state":18,"zip":18,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Hong Kong","HK",{"type":40,"coordinates":41},"Point",[42,43],114.17469,22.27832,{"lat":43,"lon":42},[46],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100628221","vitamin-d-for-acute-intracerebral-hemorrhage-100628221",false,"NCT07458815","Vitamin D for Acute Intracerebral Hemorrhage","Vitamin D Treatment in IntraCerebal Hemorrhage To Enhance Hematoma Resolution (VICToHR): a Pilot Study","VICToHR","Inclusion Criteria:\n\n* Spontaneous ICH diagnosis\n* Age ≥ 18 years\n* Within 96 hours of ICH\n* Premorbid Modified Rankin Scale of ≤2\n* Supratentorial ICH\n* ICH volume ≥2 mL\n\nExclusion Criteria:\n\n* Expected life expectancy of \\\u003C1 year\n* Glasgow Coma Scale \\\u003C9\n* Anticipated surgical evacuation of hematoma\n* Inability to participate in follow-up activity\n* Hypercalcemia\n* Hyperphosphatemia\n* History of kidney stones\n* Bleeding tendency\n* Severe renal impairment\n* Severe liver impairment\n* Known contraindication or allergy to vitamin D","ALL","18 Years","90 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"NA","Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects.\n\nVICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.",[68],"Intracerebral Hemorrhage",[70,22],"Intracerebral hemorrhage","2026-04-29",{"date":73,"type":74},"2026-05-06","ACTUAL",{"date":76,"type":74},"2026-03-01",{"date":78,"type":62},"2028-02-28",{"name":5,"class":6},1]